Fudan-Zhangjiang subscribes to RMB170m structured deposit products

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has subscribed to RMB170 million in structured deposit products from Bank of China. This utilizes temporary idle proceeds from its A shares public issuance, aligning with the company's objective to enhance capital gain and ensure liquidity.

The first agreement, for RMB40 million, is effective October 13, 2025, with a 63-day term and an expected annualized return rate between 0.5500% and 1.7000%. The second agreement, for RMB130 million, is effective October 14, 2025, with a 78-day term and an expected annualized return rate ranging from 0.3500% to 1.5575%. Both products are principal-guaranteed with floating returns and assessed as low-risk.

This transaction is a disclosable transaction under HKEX Listing Rules, as one or more applicable percentage ratios exceed 5% but remain below 25%. It is subject to reporting and announcement requirements but is exempt from shareholders' approval. The directors view the agreements as being on normal commercial terms, fair, reasonable, and in the best interests of the company and its shareholders.